Vol. 5, No. 075 |
Underwriter: |
|
Resources: |
.gif) |
ZERO, Others Endorse Key Priorities at House Committee on Oversight and Government Reform
In This Issue:
LEAD
- ZERO, Others Endorse Key Priorities at House Committee on Oversight and Government Reform
- PSA Remains An Important Tool for Fighting Cancer, Says Prostate Cancer Foundation
- The Life-Saving Benefits of PSA Screening
- Specialty May Bias Doctors' Prostate Cancer Advice
WHAT'S NEW AT ZERO
- Deadline Extended: Write to Your U.S. Representative TODAY to Support the 'Marshall-King Dear Colleague Letter'
- Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
- DASH FOR DAD' Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
- Register Now to Join the 2010 DASH FOR DAD Team
- Join the Drive Against Prostate Cancer by Supporting 'Pennies for Prostates'
RESEARCH AND TREATMENT UPDATE
- New Drug Offers Last-Ditch Hope for Prostate Cancer Patients
- Docetaxel Plus Estramustine Can Improve Response in High-Risk Localised Prostate Cancer: Presented at ASCO-GU
- Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU
- 'Tame' Virus Could Prove Prostate Cancer Weapon
[Advertisement]
|
Lead
ZERO, Others Endorse Key Priorities at House Committee on Oversight and Government Reform
ZERO joins other organizations in representing your interests on Capitol Hill.
PSA Remains An Important Tool for Fighting Cancer, Says Prostate Cancer Foundation
"Every man has the right to know if he has cancer and to make informed decisions with his urologist," and the Foundation also believes men should get a baseline PSA test beginning at age 40.
The Life-Saving Benefits of PSA Screening
One of the nation's leading experts on prostate cancer says "although the PSA test is not perfect, it is effective in identifying men at high risk for prostate cancer and for detecting it early."
Specialty May Bias Doctors' Prostate Cancer Advice
New research suggests that the type of specialist a prostate cancer patient sees - rather than his own preferences - may determine the treatment he receives.
[Advertisement]
|
What's New at ZERO
Deadline Extended: Write to Your U.S. Representative TODAY to Support the 'Marshall-King Dear Colleague Letter'
Drop What You're Doing and Write Now to Request Increased Research Funding
 |
||
Breast cancer and prostate cancer have roughly the same caseload, yet the government spends about twice as much on breast cancer research. While breast cancer deserves all the dollars it receives, it's time to stand up and demand more funding for prostate cancer.
It takes two minutes. We promise.
U.S. Representatives Jim Marshall (GA) and Peter King (NY) are now circulating a letter among their House colleagues to seek their support for increased funding for the Prostate Cancer Research Program (which is part of the Congressionally Directed Medical Research Program at the Department of Defense.)
The Prostate Cancer Research Program's funding has been stagnant at about $80 million for the last nine years. As a result, grants to continue research into clinical trials have slowed to a halt -- unless Congress acts.
Please write and ask your Representative today to support the Marshall-King Dear Colleague letter. The deadline for Members of the House to sign the letter has been extended and is now March 12, 2010.
Your active support can make the critical difference!
Register for the 2010 'Summit to End Prostate Cancer' in Washington, D.C.
 |
||
You can make a positive impact this Fall by representing ZERO and the entire prostate cancer community in Washington, D.C. Registration for the 2010 "Summit to End Prostate Cancer" is now open!
This year's 2010 Summit, scheduled for September 14-16, will focus on effective strategies for increasing the Federal investment in prostate cancer research. During the Summit, participants will have the opportunity to meet with their elected officials on Capitol Hill and learn more about the federal legislative process.
'DASH FOR DAD' Race Series Coming to 11 Cities to Raise Prostate Cancer Awareness
As National Race Series Expands Across U.S. in 2010, Supporters Are Encouraged to Bring This Event to Their City
Lace up your sneakers and join us in the race to end prostate cancer!
DASH FOR DAD, the premier prostate cancer race series in the U.S., is a heartfelt tight-knit community event that brings together athletes, cancer survivors, physicians, caregivers, family members and friends. Proceeds from each 10K race are used to provide free prostate cancer testing for men in the local community of the event.
ZERO - The Project to End Prostate Cancer with sponsors from across the country has grown the DASH FOR DAD and its partner races - the Great Prostate Cancer Challenge - to include 11 cities and an expected 5,000 runners competing in 2010.
The DASH FOR DAD or partnering Great Prostate Cancer Challenge 5K will be held in the following cities during September, known as "National Prostate Cancer Awareness Month":
 |
||
- Baltimore, MD
- Buffalo, NY
- Central FL
- Columbus, OH
- Harrisburg, PA
- Indianapolis, IN
- Kansas City, MO
- Long Island, NY
- Memphis, TN
- Nashville, TN
- Washington, DC metro area (Alexandria, VA)
Since the national race series began in 2008, more than $1 million has been raised to promote prostate cancer awareness, early detection and research. Many runners create teams and collect monetary pledges from family and friends to boost funding for local prostate cancer services.
Hosting a DASH FOR DAD is a significant way to promote prostate cancer awareness in your area - and there is still time to bring this race to your city!
Urology medical practices and other supporting organizations are especially encouraged to organize a DASH FOR DAD, due to the importance of providing free prostate cancer testing and promoting research for a cure. Click here to download the DASH FOR DAD race application.
"DASH FOR DAD elevates prostate cancer awareness to a broader nationwide level," said ZERO's CEO Skip Lockwood. "We all know someone who is impacted by this most commonly diagnosed cancer among men, striking one in every six. That's why we must do all that we can to put an end to this horrible disease."
For more information about the DASH FOR DAD 10K or if you're interested in hosting a DASH FOR DAD run in your neighborhood, contact Tracy Cesaretti.
Register Now to Join 2010 DASH FOR DAD Team
 |
||
Help fight prostate cancer by joining ZERO's DASH FOR DAD Endurance Team!
Even though the team is now complete for the Nautica New York City Triathlon in July, you still have time to sign up to be among the runners on the DASH FOR DAD Endurance Team in the Bank of America Chicago Marathon on October 10, 2010.
These race slots go quickly, so please sign up soon! For more information, contact Tracy Cesaretti at 202-303-3111.
If you're unable to make the Chicago race, you have other options available.
ZERO's DASH FOR DAD Endurance Team for the Marine Corps Marathon in Washington, D.C. is coming on October 24, or you can sign up to participate in the ING New York City Marathon on November 7.
Every dollar raised goes toward free prostate cancer testing for men across the U.S.
ZERO - The Project to End Prostate Cancer provides you with fundraising advice and support, your own donation website and list-serv, and other tools to make your participation in these races highly memorable and successful.
Join the Drive Against Prostate Cancer by Supporting 'Pennies for Prostates'
Now is your chance to take command, sit in the driver's seat, and put the 'pedal to the metal' to show your support for the prostate cancer community.
That's what Robin Sparrow plans to do this April, driving his BMW more than 3,000 miles in 12 days as part of the One Lap of America Race - the "real life" Cannonball Run.
[Advertisement]
|
Research and Treatment Update
New Drug Offers Last-Ditch Hope for Prostate Cancer Patients
An experimental new drug may increase survival by 30 percent in men with advanced disease that has become resistant to all other forms of treatment.
The cancer drug cabazitaxel increases survival to just over 15 months compared to about 12 and half months for those taking the drug mitoxantrone, according to this Tulane University research.
Docetaxel Plus Estramustine Can Improve Response in High-Risk Localised Prostate Cancer: Presented at ASCO-GU
The combination of these two drugs, as an added component to standard therapy, indicates a promising PSA response among those with high-risk, localized cancer, according to this French research.
Millennium Announces First Clinical Data For TAK-700 Prostate Molecule At ASCO GU
Initial clinical trial research shows positive results for the drug TAK-700 among patients with metastatic castration resistant prostate cancer. TAK-700 is a non-steroidal androgen synthesis inhibitor of the 17,20 lyase enzyme, a key factor in the production of steroidal hormones.
'Tame' Virus Could Prove Prostate Cancer Weapon
An injection of this virus was linked to the death of cancer cells in tumors, this Canadian research shows, yet there was no sign of the virus impacting non-cancerous tissues.
AWARE Ad Specs
PSA Standardization DVD: